Turning Point Brands, Inc. (TPB) Form 8-K — Nov 9, 2026
Turning Point Brands reported Q3 2026 net sales of $151.1 million, up 27.0%, with Modern Oral net sales doubling to $74.4 million and now representing 49.2% of total company net sales. However, profitability fell sharply: net income dropped 81.4% to $3.9 million and Adjusted EBITDA fell 41.3% to $18.4 million, as SG&A surged 69.1% to $75.3 million on heavy FRE and ALP nicotine pouch sales and marketing investment and FDA PMTA costs of $3.2 million. New CEO David Glazek struck an optimistic tone, and the company reaffirmed full-year 2026 guidance including Modern Oral gross sales of $330-$350 million and Adjusted EBITDA of $70-$80 million.
Key figures
- Eps
- 0.19
- Revenue
- 151100000
- Guidance
- Reaffirmed FY2026: Modern Oral Gross Sales $330-$350M, Modern Oral Net Sales $260-$270M, Adjusted EBITDA $70-$80M
- Net Income
- 3900000
- Total Debt
- 294405000
- Revenue Yoy
- 27.0%
- Total Assets
- 846651000
- Cash Position
- 251300000
- Shares Outstanding
- 19881761
- Sga
- $75.3M (+69.1%)
- Buyback
- 167,161 shares for $10.0M at avg $59.82
- Net debt
- $48.7M
- Adjusted ebitda
- $18.4M (down 41.3%)
- Total liquidity
- $322.8M
- Adjusted diluted eps
- $0.41 vs $1.05 prior year
- Modern oral net sales
- $74.4M (+102.9%, 49.2% of total net sales)
- Modern oral gross sales
- $93.9M (+114.2%)
- Zigzag segment net sales
- $37.3M (-15.5%)
- Stokers segment net sales
- $113.8M (+52.0%)
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.